Miscellaneous
Cristina Mussini discusses the current data on interleukin inhibitors for the treatment of COVID-19 and explores why tocilizumab has been associated with beneficial outcomes in some studies but not others.
Repurposing rheumatology drugs for COVID-19: Interleukin inhibitors
Share: